Research Grade Anti-Flu A (H3N2) HA/Hemagglutinin Broadly Neutralizing Antibody (CR8020)

Catalog No.	VK515096
Host species	Human
Species reactivity	Influenza A virus (strain A/Hong Kong/1/1968 H3N2)
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4.
Purity	>95% purity as determined by SDS-PAGE.
Isotype	IgG1-lambda
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Target	Hemagglutinin, Hemagglutinin HA1 chain, Hemagglutinin HA2 chain, HA
Purification	Protein A/G purified from cell culture supernatant.
Endotoxin level	Please contact the lab for this information.
Expression system	Mammalian Cells
Accession	Q91MA7
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Clone ID	CR8020
Note	For research use only. Not suitable for clinical or therapeutic use.

CR8020 is a broadly neutralizing antibody (bNAb) targeting the stem region of influenza A virus (IAV) hemagglutinin (HA) and is in phase II trials for prophylactic use against group 2 IAVs. Structural and computational analyses show that CR8020 binds HA residues subject to antigenic drift and host selection pressure, with escape mutations observed in some H7N9 strains. Additionally, effective engagement of Fcγ receptors (FcγR) is crucial for antibody efficacy, but membrane steric hindrance may limit HA-CR8020-FcγR complex formation. These findings highlight epitope mutability and immune complex accessibility as key factors in bNAb development.